The Committee further considered that the benefit/ risk balance concerning the use of moxifloxacin up to 14 days in the PID indication remains positive, and that information and recommendations on the use of moxifloxacin, and the measures that should be taken before it is prescribed, are adequately addressed in the ‘ contraindications’ and ‘ special warnings and precautions for use’ sections of the EU SPC.